Casirivimab/imdevimab appeared to lower the incidence of symptomatic COVID-19 in an infected, but asymptomatic, group. Editorialists urge caution, however, in interpreting the results.
Source: https://www.medscape.com/viewarticle/967798?src=mbl_msp_android&ref=share